Lilly pull-back hits local Virginia development
Eli Lilly and Co.’s decision last week to end construction on its $325 million insulin production plant near Washington, D.C., is a “clear blow” to the area’s attempts to launch a biotechnology industry, according to The Washington Examiner. Still, the newspaper reported, Prince William County, Va., will overcome the setback and attract international companies to […]